The following clinical trials represent a selection of key studies that are currently recruiting patients with rheumatoid arthritis for inclusion in investigations of new therapies and new regimens of existing treatments for patients with rheumatoid arthritis. Each clinical trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov.

Medical practices entered a strange new world of patient safety requirements during the COVID-19 pandemic, and life will never again be the same. Regardless of size or specialty, all medical practices face significant challenges to protect their patients, community, and staff by reducing the risk of spreading the COVID-19 virus, while simultaneously maintaining their financial viability.

Earlier this year, the American College of Rheumatology (ACR) published an updated version of its guideline for the management of patients with gout. This guideline features 42 recommendations, including 16 strong recommendations, the most prominent of which concerned indications for and use of pharmacologic urate-lowering therapy (ULT) “for all patients with tophaceous gout, radiographic damage due to gout, or frequent gout flares.”